A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996Phase 3Recruiting
- Lead sponsor
- BeOne Medicines (Industry)
- Enrollment
- 300 (estimated)
- Start date
- 5 Mar 2025
- Primary completion
- 31 Aug 2028 (estimated)
- Study completion
- 30 Mar 2032
- Last update posted
- 29 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Double
- Arms
- 2
Interventions
- Sonrotoclax Drug
- Zanubrutinib Drug
- Placebo Drug
Conditions and primary outcome
- Mantle Cell Lymphoma
- B Cell Lymphoma
Primary outcome
Progression-Free Survival (PFS) as assessed by Blinded Independent Review Committee (BIRC) (Approximately 41 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06742996.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06742996 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.